Stimulating regeneration in the damaged spinal cord.
Great progress has been made in recent years in experimental strategies for spinal cord repair. In this review we describe two of these strategies, namely the use of neurotrophic factors to promote functional regeneration across the dorsal root entry zone (DREZ), and the use of synthetic fibronectin conduits to support directed axonal growth. The junction between the peripheral nervous system (PNS) and central nervous system (CNS) is marked by a specialized region, the DREZ, where sensory axons enter the spinal cord from the dorsal roots. After injury to dorsal roots, axons will regenerate as far as the DREZ but no further. However, recent studies have shown that this barrier can be overcome and function restored. In animals treated with neurotrophic factors, regenerating axons cross the DREZ and establish functional connections with dorsal horn cells. For example, intrathecal delivery of neurotrophin 3 (NT3) supports ingrowth of A fibres into the dorsal horn. This ingrowth is revealed using a transganglionic anatomical tracer (cholera toxin subunit B) and analysis at light and electron microscopic level. In addition to promoting axonal growth, spinal cord repair is likely to require strategies for supporting long-distance regeneration. Synthetic fibronectin conduits may be useful for this purpose. Experimental studies indicate that fibronectin mats implanted into the spinal cord will integrate with the host tissue and support extensive and directional axonal growth. Growth of both PNS and CNS axons is supported by the fibronectin, and axons become myelinated by Schwann cells. Ongoing studies are aimed at developing composite conduits and promoting axonal growth from the fibronectin back into the spinal cord.
Priestley
J V
JV
Department of Neuroscience, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Mile End Road, London E1 4NS, UK. j.v.priestley@qmw.ac.uk
Ramer
M S
MS
King
V R
VR
McMahon
S B
SB
Brown
R A
RA
D000818:Animals; D005353:Fibronectins / Q000627:therapeutic use; D006801:Humans; D009416:Nerve Regeneration; D019736:Prostheses and Implants; D013119:Spinal Cord Injuries / Q000503:physiopathology* / Q000628:therapy*
D005353:Fibronectins